MX2023011027A - Derivados de pirimidina utiles como inhibidores de la proteina cinasa de repeticion 2 rica en leucina (lrrk2). - Google Patents
Derivados de pirimidina utiles como inhibidores de la proteina cinasa de repeticion 2 rica en leucina (lrrk2).Info
- Publication number
- MX2023011027A MX2023011027A MX2023011027A MX2023011027A MX2023011027A MX 2023011027 A MX2023011027 A MX 2023011027A MX 2023011027 A MX2023011027 A MX 2023011027A MX 2023011027 A MX2023011027 A MX 2023011027A MX 2023011027 A MX2023011027 A MX 2023011027A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- lrrk2 kinase
- kinase inhibitors
- pyrimidine derivatives
- derivatives useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164804P | 2021-03-23 | 2021-03-23 | |
| PCT/US2022/021573 WO2022204299A1 (en) | 2021-03-23 | 2022-03-23 | Pyrimidine derivatives useful as lrrk2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011027A true MX2023011027A (es) | 2023-09-27 |
Family
ID=81328290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011027A MX2023011027A (es) | 2021-03-23 | 2022-03-23 | Derivados de pirimidina utiles como inhibidores de la proteina cinasa de repeticion 2 rica en leucina (lrrk2). |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11578061B2 (https=) |
| EP (1) | EP4313955A1 (https=) |
| JP (1) | JP2024512024A (https=) |
| KR (1) | KR20230170684A (https=) |
| CN (1) | CN117355507A (https=) |
| AU (1) | AU2022246081A1 (https=) |
| BR (1) | BR112023019388A2 (https=) |
| CA (1) | CA3214360A1 (https=) |
| CO (1) | CO2023012903A2 (https=) |
| IL (1) | IL306008A (https=) |
| MX (1) | MX2023011027A (https=) |
| WO (1) | WO2022204299A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024512024A (ja) | 2021-03-23 | 2024-03-18 | ハリア・セラピューティクス・インコーポレイテッド | Ｌｒｒｋ２キナーゼ阻害剤として有用なピリミジン誘導体 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0619343D0 (en) | 2006-09-30 | 2006-11-08 | Vernalis R&D Ltd | New chemical compounds |
| TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| KR101445012B1 (ko) | 2009-12-17 | 2014-09-26 | 머크 샤프 앤드 돔 코포레이션 | Ｓｙｋ 억제제로서의 아미노피리미딘 |
| EP2512246B1 (en) | 2009-12-17 | 2015-09-30 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
| ES2577829T3 (es) | 2010-06-04 | 2016-07-19 | F. Hoffmann-La Roche Ag | Derivados de aminopirimidina como moduladores de la LRRK2 |
| NO2638031T3 (https=) * | 2010-11-10 | 2018-03-10 | ||
| AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| NO3004079T3 (https=) | 2013-06-04 | 2018-06-16 | ||
| RU2016134751A (ru) | 2014-01-29 | 2018-03-02 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
| EP3144292B1 (en) | 2014-04-14 | 2020-08-26 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd | 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| US11174248B2 (en) | 2017-10-11 | 2021-11-16 | Merck Sharp & Dohme Corp. | Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof |
| JP7208240B2 (ja) | 2017-12-19 | 2023-01-18 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸トリアゾールアジン |
| CN110872277B (zh) | 2019-11-14 | 2021-06-04 | 浙江大学 | N-取代芳环-2-氨基嘧啶类化合物及用途 |
| JP2024512024A (ja) * | 2021-03-23 | 2024-03-18 | ハリア・セラピューティクス・インコーポレイテッド | Ｌｒｒｋ２キナーゼ阻害剤として有用なピリミジン誘導体 |
-
2022
- 2022-03-23 JP JP2023558377A patent/JP2024512024A/ja active Pending
- 2022-03-23 CN CN202280036432.0A patent/CN117355507A/zh active Pending
- 2022-03-23 CA CA3214360A patent/CA3214360A1/en active Pending
- 2022-03-23 MX MX2023011027A patent/MX2023011027A/es unknown
- 2022-03-23 AU AU2022246081A patent/AU2022246081A1/en active Pending
- 2022-03-23 WO PCT/US2022/021573 patent/WO2022204299A1/en not_active Ceased
- 2022-03-23 EP EP22715927.4A patent/EP4313955A1/en active Pending
- 2022-03-23 BR BR112023019388A patent/BR112023019388A2/pt unknown
- 2022-03-23 IL IL306008A patent/IL306008A/en unknown
- 2022-03-23 US US17/702,600 patent/US11578061B2/en active Active
- 2022-03-23 KR KR1020237035536A patent/KR20230170684A/ko active Pending
- 2022-12-13 US US18/065,259 patent/US11866423B2/en active Active
-
2023
- 2023-09-28 CO CONC2023/0012903A patent/CO2023012903A2/es unknown
- 2023-11-20 US US18/514,959 patent/US12428404B2/en active Active
-
2025
- 2025-09-04 US US19/319,120 patent/US20260055087A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12428404B2 (en) | 2025-09-30 |
| WO2022204299A1 (en) | 2022-09-29 |
| US20230183217A1 (en) | 2023-06-15 |
| JP2024512024A (ja) | 2024-03-18 |
| CO2023012903A2 (es) | 2023-10-09 |
| US20220324845A1 (en) | 2022-10-13 |
| AU2022246081A1 (en) | 2023-10-12 |
| EP4313955A1 (en) | 2024-02-07 |
| KR20230170684A (ko) | 2023-12-19 |
| BR112023019388A2 (pt) | 2023-11-07 |
| US20260055087A1 (en) | 2026-02-26 |
| IL306008A (en) | 2023-11-01 |
| CN117355507A (zh) | 2024-01-05 |
| CA3214360A1 (en) | 2022-09-29 |
| US11578061B2 (en) | 2023-02-14 |
| US11866423B2 (en) | 2024-01-09 |
| US20240190848A1 (en) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022553024A1 (en) | Inhibitors of nek7 kinase | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| MX2021005924A (es) | Compuestos y metodos de uso de los mismos para el tratamiento del cancer. | |
| MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
| WO2020227549A8 (en) | MODULATORS OF THR-β AND METHODS OF USE THEREOF | |
| MX2020013373A (es) | Compuestos de naftiridinona utiles como activadores de celulas t. | |
| MX2022007842A (es) | Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t. | |
| MX2019013954A (es) | Inhibidores covalentes de kras. | |
| PH12023552774A1 (en) | Nek7 inhibitors | |
| CR20200503A (es) | Inhibidores de cinasa dependientes de ciclina | |
| MX2022015495A (es) | Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7). | |
| WO2016164675A8 (en) | Substituted quinazoline compounds and methods of use thereof | |
| MY189118A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | |
| MY207787A (en) | Alpha-d-galactopyranoside derivatives | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| MX2023004033A (es) | Espiro derivados de alfa-d-galactopiranosidos. | |
| WO2020247298A3 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| CR20210181A (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| MX418886B (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. | |
| MX2022016516A (es) | Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso. | |
| MX2025002166A (es) | Compuestos y metodos para modular her2 | |
| CR20230218A (es) | Nuevos derivados de indazol acetileno | |
| MX2023011027A (es) | Derivados de pirimidina utiles como inhibidores de la proteina cinasa de repeticion 2 rica en leucina (lrrk2). |